Cancer vaccine NY-ESO-1 - Dendreon

Drug Profile

Cancer vaccine NY-ESO-1 - Dendreon

Alternative Names: APC80NY; Cancer vaccine NY-ESO - Dendreon

Latest Information Update: 31 Mar 2008

Price : $50

At a glance

  • Originator Dendreon Corporation
  • Class Cancer vaccines; Dendritic cell vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 22 Nov 2006 Preclinical development is still ongoing for Cancer in USA
  • 12 Oct 2004 This vaccine is still in active development
  • 24 Sep 2002 This vaccine is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top